ArticleScientific reports2023

MasitinibL shows promise as a drug-like analog of masitinib that elicits comparable SARS-Cov-2 3CLpro inhibition with low kinase preference.

Olanrewaju Ayodeji Durojaye et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.